The Cancer Hope Premium: Why Your FDA-Approved Drug Now Comes With A $49,999 "Access Fee"
MAY 20, 2026 — The FDA announced today that two new cancer treatments have been approved: Bizengri for NRG1 fusion-positive cholangiocarcinoma and Enhertu for early HER2-positive breast cancer. But before patients can receive these life-saving medications, they must first navigate a compliance labyrinth that threatens to cost more than the drugs themselves.
Bizengri: The $499,999 Hope
Bizengri (zenocutuzumab-zbco) has been approved as the first FDA-authorized treatment for unresectable or metastatic NRG1 fusion-positive cholangiocarcinoma that has progressed after prior therapies. This rare subtype of bile duct cancer affects fewer than 500 patients annually, yet the approval documentation requires: